Two compound classes that often get bundled together in online discussions: research peptides and SARMs (selective androgen receptor modulators). They get mentioned in the same conversations, the same forums, and sometimes the same product catalogues — but biochemically and pharmacologically they have almost nothing in common. This guide walks through what each class actually is, how they differ in structure and mechanism, and why the comparison matters for anyone surveying the research landscape in Australia.
This article is a research-context comparison only. Optic Labs supplies peptides for laboratory research; we do not supply SARMs. Nothing in this article is medical, therapeutic, or dosing advice — see the disclaimer at the end.
What peptides actually are
Peptides are short chains of amino acids — typically between 2 and roughly 50 residues, depending on definition — linked by peptide bonds. They are the same fundamental building block class as proteins, just shorter. The body produces thousands of endogenous peptides (insulin, oxytocin, ghrelin, the endorphins) and synthetic research peptides are designed to either mimic, modify, or antagonise these natural signalling molecules.
A research peptide like BPC-157 is a 15-amino-acid sequence. TB-500 is a 17-amino-acid fragment of thymosin beta-4. CJC-1295 with Ipamorelin combines a 30-residue GHRH analogue with a 5-residue ghrelin mimetic. They act primarily through cell-surface receptors — GHSR-1a, GHRHR, formyl peptide receptors, and others — triggering downstream signalling cascades. Because peptides are protein-based, they are typically administered subcutaneously in research settings; oral bioavailability is generally poor due to digestive degradation. For a longer overview of the category see our complete 2025 research guide to peptides in Australia.
What SARMs actually are
SARMs — selective androgen receptor modulators — are a class of small-molecule, non-steroidal compounds that bind to the androgen receptor. They are not peptides. They are not protein-based at all. They are synthetic organic compounds with molecular weights typically in the 300–500 Dalton range, structurally closer to a pharmaceutical small molecule than to anything biological the body produces endogenously. Examples discussed in research literature include ostarine (MK-2866), ligandrol (LGD-4033), RAD-140, and andarine (S-4).
The "selective" in the name refers to tissue selectivity at the androgen receptor: SARMs were developed in pharmaceutical research with the goal of producing anabolic effects on muscle and bone while minimising activity at prostate, liver, and other non-target tissues that traditional anabolic-androgenic steroids affect. Whether that selectivity holds up in real-world use is a separate research question. The structural reality is that SARMs are oral-active small molecules; peptides are injectable protein fragments. They sit in completely different chemical universes.
Mechanism: receptor targets and signalling
The mechanistic divergence is where the comparison stops being a comparison at all. SARMs act on a single intracellular receptor — the androgen receptor (AR), a nuclear hormone receptor. When a SARM binds AR, the receptor translocates to the nucleus and acts as a transcription factor, regulating gene expression in androgen-responsive tissues. Everything a SARM does, in research models, traces back to that single AR pathway.
Peptides, as a class, are mechanistically heterogeneous. Different peptides act on different receptors. BPC-157 is studied for nitric-oxide pathway interactions and modulation of growth factors like VEGF. CJC-1295 and Ipamorelin stimulate the pituitary somatotrophs through GHRHR and GHSR-1a respectively. Tesamorelin is also a GHRH analogue but with a different half-life and tissue distribution profile — see our tesamorelin research guide. PT-141 targets melanocortin receptors. Selank influences GABAergic and serotonergic systems. There is no single "peptide pathway" — there are dozens of distinct mechanisms studied across the category.
Regulatory and legal status in Australia
In Australia, both classes are regulated, and the regulatory framework is different for each. Most research peptides used in laboratory settings are Schedule 4 (Prescription Only Medicine) under the Poisons Standard, and SARMs are Schedule 4 as well — but the underlying regulatory rationale and TGA classification pathway differs. SARMs additionally appear on the World Anti-Doping Agency (WADA) Prohibited List under section S1.2 (other anabolic agents), making them banned in essentially all sanctioned sport. Some peptides also appear on the WADA list (notably the GH-secretagogue category that includes CJC-1295 and Ipamorelin), but the WADA categorisation is split across multiple sections rather than concentrated under one anabolic-agent banner.
From a sourcing and importation standpoint in Australia, both classes are subject to TGA oversight, customs interception, and Schedule 4 supply rules. For a closer look at how these rules work in practice, see our TGA compliance guide for research peptides. SARMs face the same Schedule 4 framework but with the additional WADA prohibition layer. Optic Labs does not supply SARMs; we supply research peptides for laboratory use only.
How research literature treats the two classes
The published literature on peptides spans decades, with substantial clinical-trial data on certain compounds (tesamorelin has FDA approval for HIV-associated lipodystrophy; sermorelin and several GHRH analogues have an extensive endocrinology literature; melanocortin agonists have published trial data). Other peptides remain primarily in preclinical or early-stage research with limited human evidence — BPC-157 is an example where preclinical data is extensive but human trials are sparse.
The SARM literature is younger and structurally different. Ostarine has been through several phase 2 trials for muscle-wasting conditions, but no SARM has received regulatory approval anywhere in the world for any human indication. The development pipeline has stalled at phase 2/3 for most candidates, with companies abandoning programmes over hepatotoxicity signals, cardiovascular concerns, or commercial viability questions. The research evidence base for SARMs in humans is therefore narrower and more recent than the peptide literature, and most of the secondary discussion about SARMs comes from non-clinical sources rather than peer-reviewed trial data. For a curated view of evidence-ranked peptide options, see our best peptides in Australia 2025: ranked by evidence.
Frequently asked questions
Are SARMs peptides?
No. SARMs are non-peptide small-molecule compounds that bind the androgen receptor. Peptides are short chains of amino acids linked by peptide bonds. The two classes share no structural relationship — they are separate categories of research compound. The confusion sometimes arises because both are discussed in the same online research-compound communities, but biochemically they are unrelated.
Is MK-677 a SARM or a peptide?
Neither, technically. MK-677 (ibutamoren) is a non-peptide small-molecule ghrelin-receptor agonist — it acts at GHSR-1a, the same receptor that Ipamorelin targets, but MK-677 itself is not a peptide. It is also not an androgen receptor modulator, so it is not a SARM. It sits in its own category as an oral-active GH secretagogue. This compound regularly appears in "SARMs vs peptides" discussions because it is sold by SARM vendors despite being mechanistically more aligned with the GH-peptide research category.
Are SARMs and peptides the same?
No, the two are not the same and should not be conflated. They differ in molecular structure (small-molecule vs amino-acid chain), administration route (typically oral vs typically subcutaneous), receptor targets (single AR pathway vs many distinct receptors), regulatory pathway (both Schedule 4 in Australia but with different categorisation under WADA), and research evidence base (decades vs roughly 15 years of significant publication). The shared online context is essentially the only thing that links them.
Can peptides and SARMs be combined in research protocols?
This is a question that appears in research-community discussions but has effectively no controlled human-trial data behind it. Combining compounds from two pharmacologically unrelated classes — one acting on AR transcription, the other on diverse cell-surface receptors — would require its own dedicated safety and interaction research that has not been conducted. Optic Labs does not provide combination protocol guidance, and we do not supply SARMs. Anyone designing research protocols should consult primary literature for each compound class independently and consider that combination data is largely absent.
Disclaimer
This article is for research and educational context only. Research peptides supplied by Optic Labs are intended for laboratory and in vitro research use; they are not therapeutic products and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. Optic Labs does not supply SARMs. Nothing in this article constitutes medical, therapeutic, dosing, or compliance advice. Australian regulations under the Therapeutic Goods Act and the Poisons Standard apply to both compound classes; researchers and individuals should verify current TGA and Poisons Standard listings before any acquisition or use. Speak with a qualified Australian medical practitioner about any health-related decision.